Vanessa Patel - Publications

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals.

Journal: Cureus

Published: May 17, 2026

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Journal: Breast cancer research and treatment

Published: February 28, 2026

Assessment of Immune Cell Populations in the Peripheral Blood of Patients With Metastatic Prostate Cancer.

Journal: Cureus

Published: March 14, 2025

Prevalence of Somatic BReast CAncer Gene (BRCA) 1 and 2 Pathogenic Variants in Portuguese Metastatic Prostate Cancer Patients.

Journal: Cureus

Published: February 04, 2025

CDK4/6 Inhibitors-Induced Macrocytosis Is Not Associated with Hemolysis and Does Not Impact Hemoglobin Homeostasis.

Journal: Cancers

Published: January 28, 2025

Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 21, 2025

DNA damage targeted therapy for advanced breast cancer.

Journal: Exploration of targeted anti-tumor therapy

Published: August 30, 2023

Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes.

Journal: Cells

Published: July 05, 2023

Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence.

Journal: Clinical drug investigation

Published: July 03, 2023